We will be attending the XIX International Symposium on Amyloidosis, taking place in Rochester, Minesota. Organised in collaboration with the ISA Board and members of Mayo Clinic, the program promises to be both informative and engaging.

The symposium will feature a comprehensive scientific program covering various types of systemic amyloidosis, including ATTR (hereditary and wild-type), AL (light-chain), AA, and less frequent forms.

The program will delve into the basic science, pathophysiology, diagnosis, and current and emerging treatments of systemic amyloidosis. Participants will have the opportunity to learn from competitive oral and poster abstracts, gaining insights into the latest advancements in the field.

We encourage you to join Dr. Taubel and other experts in the field for what promises to be an enlightening and educational experience. 

To find out more: https://cveducation.mayo.edu/store/international-symposium-on-amyloidosis 

Latest news

Richmond enrols first patients in Verve Therapeutic’s Heart-2 trial - pioneering a new approach to cardiovascular disease

June 27, 2024
Richmond enrols and doses the first patient in a clinical trial aimed at transforming the care of cardiovascular disease with single treatment gene-editing medicines.
Read more

A first of a kind trial in the fight against malaria

June 12, 2024
Richmond successfully recruits and enrols adults of sub-Saharan ancestry who all complete a first of its kind trial in the treatment of malaria.
Read more


AHA Hypertension Scientific Sessions 2024

5 - 8 September 2024
Dr. Jörg Taubel, CEO of Richmond Pharmacology, will be attending the Hypertension 2024 Scientific Sessions
View event